Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

August 01, 1996; Volume 50,Issue 2
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Ahmad, S

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  2. Akhtar, S

    1. You have access
      A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
      J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
      Molecular Pharmacology August 1996, 50 (2) 314-325;
  3. Alzola, E S

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;
  4. André, C

    1. You have access
      Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
      S Lecoeur, C André and P H Beaune
      Molecular Pharmacology August 1996, 50 (2) 326-333;
  5. Aquaro, S

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
    2. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  6. Azula, F J

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;

B

  1. Backlund, M

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  2. Balestra, E

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  3. Balzarini, J

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
    2. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  4. Barnard, E A

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  5. Bateson, A N

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  6. Beaune, P H

    1. You have access
      Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
      S Lecoeur, C André and P H Beaune
      Molecular Pharmacology August 1996, 50 (2) 326-333;
  7. Beck-Sickinger, A G

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  8. Beinborn, M

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  9. Beindl, W

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;
  10. Bell, G I

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  11. Berry, S A

    1. You have access
      Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
      S A Berry, M C Shah, N Khan and B L Roth
      Molecular Pharmacology August 1996, 50 (2) 306-313;
  12. Billings, R E

    1. You have access
      Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
      D L Duval, D R Miller, J Collier and R E Billings
      Molecular Pharmacology August 1996, 50 (2) 277-284;
  13. Bindokas, V P

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  14. Blakely, R D

    1. You have access
      Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
      H E Melikian, S Ramamoorthy, C G Tate and R D Blakely
      Molecular Pharmacology August 1996, 50 (2) 266-276;
  15. Bogatkewitsch, G S

    1. You have access
      Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
      G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen
      Molecular Pharmacology August 1996, 50 (2) 424-429;
  16. Bouchelet, I

    1. You have access
      Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
      I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
      Molecular Pharmacology August 1996, 50 (2) 219-223;
  17. Brown, A M

    1. You have access
      Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
      J Kiehn, B Wible, A E Lacerda and A M Brown
      Molecular Pharmacology August 1996, 50 (2) 380-387;
  18. Burnstock, G

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;

C

  1. Calio, R

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  2. Case, B

    1. You have access
      Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
      I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
      Molecular Pharmacology August 1996, 50 (2) 219-223;
  3. Cass, C E

    1. You have access
      Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
      S Y Yao, C E Cass and J D Young
      Molecular Pharmacology August 1996, 50 (2) 388-393;
  4. Cenci, A

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  5. Chahlavi, A

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  6. Chantry, A

    1. You have access
      A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
      J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
      Molecular Pharmacology August 1996, 50 (2) 314-325;
  7. Cohen, Z

    1. You have access
      Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
      I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
      Molecular Pharmacology August 1996, 50 (2) 219-223;
  8. Collier, J

    1. You have access
      Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
      D L Duval, D R Miller, J Collier and R E Billings
      Molecular Pharmacology August 1996, 50 (2) 277-284;
  9. Conde, M

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;
  10. Constantinou, A

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;
  11. Coulson, J M

    1. You have access
      A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
      J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
      Molecular Pharmacology August 1996, 50 (2) 314-325;

D

  1. Dalman, H M

    1. You have access
      Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
      S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
      Molecular Pharmacology August 1996, 50 (2) 351-358;
  2. Dean, N M

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  3. De Clercq, E

    1. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  4. Di Pierro, D

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  5. Drewett, J G

    1. You have access
      Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line.
      L J Olson, D G Lowe and J G Drewett
      Molecular Pharmacology August 1996, 50 (2) 430-435;
  6. Dubyak, G

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;
  7. Duval, D L

    1. You have access
      Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
      D L Duval, D R Miller, J Collier and R E Billings
      Molecular Pharmacology August 1996, 50 (2) 277-284;

E

  1. Eberlein, W

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  2. Engel, W

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;

F

  1. Freissmuth, M

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;

G

  1. Ganapathi, R

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;
  2. Gesek, F A

    1. You have access
      Alpha 2-adrenergic receptors activate phospholipase C in renal epithelial cells.
      F A Gesek
      Molecular Pharmacology August 1996, 50 (2) 407-414;
  3. Glaum, S R

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  4. Glazer, R I

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  5. Grabowski, D

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;
  6. Gustafsson, J A

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;

H

  1. Hamel, E

    1. You have access
      Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
      I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
      Molecular Pharmacology August 1996, 50 (2) 219-223;
  2. Hara, M

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  3. Harden, K

    1. You have access
      Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
      R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
      Molecular Pharmacology August 1996, 50 (2) 224-229;
  4. Harris, R A

    1. You have access
      A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
      M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
      Molecular Pharmacology August 1996, 50 (2) 402-406;
  5. Hedlund, E

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  6. Henderson, D

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  7. Herzog, H

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  8. Hohenegger, M

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;

I

  1. Ijzerman, A P

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;
  2. Irwin, W J

    1. You have access
      A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
      J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
      Molecular Pharmacology August 1996, 50 (2) 314-325;

J

  1. Jakobs, K H

    1. You have access
      Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
      G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen
      Molecular Pharmacology August 1996, 50 (2) 424-429;
  2. Jeon, Y J

    1. You have access
      Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
      Y J Jeon, K H Yang, J T Pulaski and N E Kaminski
      Molecular Pharmacology August 1996, 50 (2) 334-341;

K

  1. Kainu, T

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  2. Kamath, N

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;
  3. Kaminski, N E

    1. You have access
      Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
      Y J Jeon, K H Yang, J T Pulaski and N E Kaminski
      Molecular Pharmacology August 1996, 50 (2) 334-341;
  4. Karlsson, A

    1. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  5. Khan, N

    1. You have access
      Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
      S A Berry, M C Shah, N Khan and B L Roth
      Molecular Pharmacology August 1996, 50 (2) 306-313;
  6. Kiehn, J

    1. You have access
      Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
      J Kiehn, B Wible, A E Lacerda and A M Brown
      Molecular Pharmacology August 1996, 50 (2) 380-387;
  7. King, B F

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  8. Köhler, C

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  9. Kolakowski, L F

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  10. Kopin, A S

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  11. Krivacic, K

    1. You have access
      Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
      R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
      Molecular Pharmacology August 1996, 50 (2) 243-248;

L

  1. Lacerda, A E

    1. You have access
      Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
      J Kiehn, B Wible, A E Lacerda and A M Brown
      Molecular Pharmacology August 1996, 50 (2) 380-387;
  2. Lazarowski, E R

    1. You have access
      Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
      R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
      Molecular Pharmacology August 1996, 50 (2) 224-229;
  3. Lazzarino, G

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  4. Lecoeur, S

    1. You have access
      Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
      S Lecoeur, C André and P H Beaune
      Molecular Pharmacology August 1996, 50 (2) 326-333;
  5. Lee, C C

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  6. Lenz, W

    1. You have access
      Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
      G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen
      Molecular Pharmacology August 1996, 50 (2) 424-429;
  7. Li, Q

    1. You have access
      Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
      R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
      Molecular Pharmacology August 1996, 50 (2) 224-229;
  8. Lowe, D G

    1. You have access
      Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line.
      L J Olson, D G Lowe and J G Drewett
      Molecular Pharmacology August 1996, 50 (2) 430-435;

M

  1. Macarulla, J M

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;
  2. Marino, A

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;
  3. Martinez, R

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  4. Martuza, R L

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  5. Mascia, M P

    1. You have access
      A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
      M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
      Molecular Pharmacology August 1996, 50 (2) 402-406;
  6. Melikian, H E

    1. You have access
      Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
      H E Melikian, S Ramamoorthy, C G Tate and R D Blakely
      Molecular Pharmacology August 1996, 50 (2) 266-276;
  7. Mihic, S J

    1. You have access
      A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
      M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
      Molecular Pharmacology August 1996, 50 (2) 402-406;
  8. Miller, D R

    1. You have access
      Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
      D L Duval, D R Miller, J Collier and R E Billings
      Molecular Pharmacology August 1996, 50 (2) 277-284;
  9. Miller, R J

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  10. Mitterauer, T

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;
  11. Munoz, M

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;

N

  1. Nanoff, C

    1. You have access
      Inhibition of receptor/G protein coupling by suramin analogues.
      W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth
      Molecular Pharmacology August 1996, 50 (2) 415-423;
  2. Neubig, R R

    1. You have access
      Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
      S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
      Molecular Pharmacology August 1996, 50 (2) 351-358;
  3. Nicholas, R A

    1. You have access
      Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
      R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
      Molecular Pharmacology August 1996, 50 (2) 224-229;

O

  1. Olson, L J

    1. You have access
      Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line.
      L J Olson, D G Lowe and J G Drewett
      Molecular Pharmacology August 1996, 50 (2) 430-435;

P

  1. Panti, S

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  2. Pasternak, G W

    1. You have access
      Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.
      K M Standifer, G C Rossi and G W Pasternak
      Molecular Pharmacology August 1996, 50 (2) 293-298;
  3. Pelemans, H

    1. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  4. Pelto-Huikko, M

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  5. Perno, C F

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
    2. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  6. Polonsky, K S

    1. You have access
      Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
      S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller
      Molecular Pharmacology August 1996, 50 (2) 230-235;
  7. Poyner, D R

    1. You have access
      A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
      J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar
      Molecular Pharmacology August 1996, 50 (2) 314-325;
  8. Pratt, D S

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  9. Pulaski, J T

    1. You have access
      Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
      Y J Jeon, K H Yang, J T Pulaski and N E Kaminski
      Molecular Pharmacology August 1996, 50 (2) 334-341;

R

  1. Rabkin, S D

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  2. Ramamoorthy, S

    1. You have access
      Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
      H E Melikian, S Ramamoorthy, C G Tate and R D Blakely
      Molecular Pharmacology August 1996, 50 (2) 266-276;
  3. Robbins, J D

    1. You have access
      Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
      E M Sutkowski, J D Robbins, W J Tang and K B Seamon
      Molecular Pharmacology August 1996, 50 (2) 299-305;
  4. Rossi, G C

    1. You have access
      Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.
      K M Standifer, G C Rossi and G W Pasternak
      Molecular Pharmacology August 1996, 50 (2) 293-298;
  5. Roth, B L

    1. You have access
      Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
      S A Berry, M C Shah, N Khan and B L Roth
      Molecular Pharmacology August 1996, 50 (2) 306-313;
  6. Rudolf, K

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;

S

  1. Sautel, M

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  2. Schmitz, F

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  3. Schofield, P R

    1. You have access
      A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
      M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
      Molecular Pharmacology August 1996, 50 (2) 402-406;
  4. Schols, D

    1. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  5. Scribner, M K

    1. You have access
      Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
      S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
      Molecular Pharmacology August 1996, 50 (2) 351-358;
  6. Seamon, K B

    1. You have access
      Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
      E M Sutkowski, J D Robbins, W J Tang and K B Seamon
      Molecular Pharmacology August 1996, 50 (2) 299-305;
  7. Séguéla, P

    1. You have access
      Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
      I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel
      Molecular Pharmacology August 1996, 50 (2) 219-223;
  8. Shah, M C

    1. You have access
      Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
      S A Berry, M C Shah, N Khan and B L Roth
      Molecular Pharmacology August 1996, 50 (2) 306-313;
  9. Simon, J

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  10. Standifer, K M

    1. You have access
      Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.
      K M Standifer, G C Rossi and G W Pasternak
      Molecular Pharmacology August 1996, 50 (2) 293-298;
  11. Sutkowski, E M

    1. You have access
      Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
      E M Sutkowski, J D Robbins, W J Tang and K B Seamon
      Molecular Pharmacology August 1996, 50 (2) 299-305;

T

  1. Tang, W J

    1. You have access
      Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
      E M Sutkowski, J D Robbins, W J Tang and K B Seamon
      Molecular Pharmacology August 1996, 50 (2) 299-305;
  2. Tate, C G

    1. You have access
      Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
      H E Melikian, S Ramamoorthy, C G Tate and R D Blakely
      Molecular Pharmacology August 1996, 50 (2) 266-276;
  3. Tavazzi, B

    1. You have access
      Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
      C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio
      Molecular Pharmacology August 1996, 50 (2) 359-366;
  4. Taylor, J M

    1. You have access
      Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
      S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
      Molecular Pharmacology August 1996, 50 (2) 351-358;
  5. Trueba, M

    1. You have access
      Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
      F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino
      Molecular Pharmacology August 1996, 50 (2) 367-379;
  6. Tseng, C P

    1. You have access
      Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
      C P Tseng and A K Verma
      Molecular Pharmacology August 1996, 50 (2) 249-257;

V

  1. Valenzuela, C F

    1. You have access
      A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
      M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris
      Molecular Pharmacology August 1996, 50 (2) 402-406;
  2. Van Koppen, C J

    1. You have access
      Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
      G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen
      Molecular Pharmacology August 1996, 50 (2) 424-429;
  3. Verma, A K

    1. You have access
      Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
      C P Tseng and A K Verma
      Molecular Pharmacology August 1996, 50 (2) 249-257;

W

  1. Wade, S M

    1. You have access
      Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
      S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig
      Molecular Pharmacology August 1996, 50 (2) 351-358;
  2. Walker, P

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  3. Wang, S

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  4. Warner, M

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;
  5. Watt, W C

    1. You have access
      Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
      R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden
      Molecular Pharmacology August 1996, 50 (2) 224-229;
  6. Webb, T E

    1. You have access
      A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
      T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard
      Molecular Pharmacology August 1996, 50 (2) 258-265;
  7. Wible, B

    1. You have access
      Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
      J Kiehn, B Wible, A E Lacerda and A M Brown
      Molecular Pharmacology August 1996, 50 (2) 380-387;
  8. Wittneben, H

    1. You have access
      Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
      M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger
      Molecular Pharmacology August 1996, 50 (2) 285-292;
  9. Witvrouw, M

    1. You have access
      Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
      J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
      Molecular Pharmacology August 1996, 50 (2) 394-401;
  10. Wu, M J

    1. You have access
      Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
      F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin
      Molecular Pharmacology August 1996, 50 (2) 436-441;
  11. Wyss, A

    1. You have access
      Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
      E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner
      Molecular Pharmacology August 1996, 50 (2) 342-350;

Y

  1. Yang, K H

    1. You have access
      Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
      Y J Jeon, K H Yang, J T Pulaski and N E Kaminski
      Molecular Pharmacology August 1996, 50 (2) 334-341;
  2. Yao, S Y

    1. You have access
      Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
      S Y Yao, C E Cass and J D Young
      Molecular Pharmacology August 1996, 50 (2) 388-393;
  3. Yazaki, T

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
  4. Young, J D

    1. You have access
      Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
      S Y Yao, C E Cass and J D Young
      Molecular Pharmacology August 1996, 50 (2) 388-393;

Z

  1. Zylber-Katz, E

    1. You have access
      Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
      T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer
      Molecular Pharmacology August 1996, 50 (2) 236-242;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 2
1 Aug 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics